Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Gross Profit: 2022-2025

Historic Gross Profit for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$15,000.

  • Taysha Gene Therapies' Gross Profit fell 100.84% to -$15,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 36.51%. This contributed to the annual value of $8.3 million for FY2024, which is 46.07% down from last year.
  • Taysha Gene Therapies' Gross Profit amounted to -$15,000 in Q3 2025, which was down 100.76% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Gross Profit peaked at $4.7 million during Q3 2023, and registered a low of -$1.3 million during Q4 2022.
  • Moreover, its 3-year median value for Gross Profit was $2.3 million (2025), whereas its average is $2.6 million.
  • Its Gross Profit has fluctuated over the past 5 years, first spiked by 800.30% in 2023, then tumbled by 100.84% in 2025.
  • Taysha Gene Therapies' Gross Profit (Quarterly) stood at -$1.3 million in 2022, then surged by 376.17% to $3.6 million in 2023, then slumped by 43.90% to $2.0 million in 2024, then plummeted by 100.84% to -$15,000 in 2025.
  • Its Gross Profit stands at -$15,000 for Q3 2025, versus $2.0 million for Q2 2025 and $2.3 million for Q1 2025.